While January is not typically the best-performing month for European stocks, recent years have seen strong gains. Historical ...
In a report released today, Charles Weston from RBC Capital downgraded Sartorius Stedim Biotech to a Hold, with a price target of €240.00.
Investing.com -- RBC Capital Markets downgraded Sartorius AG to “sector perform” from “outperform” rating in a note dated ...
Key opportunities in the bioprocessing market include expansion in downstream processing, cell and gene therapies, and ...
Key market opportunities in bioprocess automation include leveraging AI and ML for enhanced process control, focusing on ...
The "Bioprocess Filtration: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for bioprocess filtration is estimated to grow from $8.4 billion in 2025 to ...
Spine surgeon Carl Sartorius, MD, has retired, effective Dec. 31, Carmel, Ind.-based Goodman Campbell Brain And Spine said. Dr. Sartorius joined the practice in 1990 when it was known as the ...
Earnings call Sartorius Stedim Biotech reported 9M 2025 sales growth of 7.5% in constant currencies (5.5% reported), with underlying EBITDA up 12.8% and margin expanding 200bps to 29.7%. Strong ...
Investing.com -- Shares of Sartorius AG rose more than 11% on Thursday following the company’s third-quarter results, which came in above expectations and led management to raise full-year guidance.
Welcome to the presentation of Sartorius and Sartorius Stedim Biotech's nine months 2025 results. Please note that the call is being recorded and streamed on Sartorius' website. Your participation in ...
Wang Xuyu, general manager of Sartorius China, addresses a summit held in Shanghai on Thursday as part of a series of events to mark the German company's 30 years of operations in the China market.
Nanotein’s NanoSpark® reagents enhance cell activation and expansion in cell therapy manufacturing Exclusive global distribution agreement for NanoSpark® activation products Joint development of new ...